Picture EBD Group BIO-Europe 2026 Köln Cologne to 31 Jul 650x100px

Product › Details

ProTide product

	Next higher product group	cancer drug
	Status	2014-04-10 development existent
	Organisation	NuCana Biomed Ltd.
	Today	NuCana plc (Nasdaq: NCNA)
	Group	NuCana plc (Nasdaq: NCNA)
	Original research	Cardiff University

Record changed: 2023-07-10

Picture EBD Group BIO-Europe 2026 Köln Cologne to 31 Jul 650x200px

More documents for cancer drug

[1] CellCentric Ltd.. (5/6/26). "Press Release: CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma". Cambridge & Boston, MA....
[2] AstraZeneca plc. (1/29/26). "Press Release: AstraZeneca Plans to Invest $15 Billion in China through 2030 to Pioneer the Next-generation of Innovative Medicines"....
[3] Infinitopes Ltd.. (1/21/26). "Press Release: Infinitopes Expands Seed Financing to $35 Million to Accelerate Clinical Development of Precision Cancer Vaccine". Oxford....
[4] ErVimmune SA. (1/21/26). "Press Release: ErVimmune Raises €17 Million in Series A First Closing to Enter Clinical Development with Lead Cancer Vaccine Candidate". Lyon....
[5] Bicycle Therapeutics plc. (12/16/25). "Press Release: Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline". Cambridge & Boston, MA....
[6] Coulter Partners. (7/10/25). "Press Release: Coulter Partners Continues Partnership with iOnctura and Places New Chief Financial Officer"....
[7] CStone Pharmaceuticals. (7/8/25). "Press Release: CStone Signs Exclusive License Agreement with Istituto Gentili for Sugemalimab in Western Europe and the UK". Suzhou....
[8] BioNTech SE. (5/5/25). "Press Release: BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer". Mainz....
[9] Oryzon Genomics S.A.. (4/24/25). "Press Release: Oryzon Raises €30 Million in Capital Increase". Madrid & Cambridge, MA....
[10] Boehringer Ingelheim. (4/23/25). "Press Release: Boehringer Ingelheim and Tessellate Bio Partner to Develop First-in-class Precision Treatments for People with Hard-to-treat Cancers". Ingelheim & Amsterdam....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)